Study of 177Lu antibody and medicines for first advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination of targeted medicines (including 177Lu girentuximab) plus immunotherapy to treat people with advanced clear cell kidney cancer who have not had prior systemic (whole-body) treatment. It aims to shrink tumors and control disease by attacking cancer in multiple ways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and be able to sign consent for the study.
- Your kidney cancer must be advanced or has spread (locally advanced or metastatic) and mainly be clear cell type.
- You must have at least one measurable tumor spot on scans.
- Your daily functioning should be good (ECOG performance status 0–1).
- Your blood counts and organ function (kidneys, liver) must meet study lab thresholds.
- You must be able to swallow pills and agree to provide tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a radioactive drug and its imaging partner to find and treat kidney cancer that has spread. You get a scan first to see if the cancer absorbs the drug, and if it does, you receive the therapy.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.